{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=79", "query": { "intervention": "Control Capsules", "page": 79 }, "page_size": 10 }, "pagination": { "page": 79, "page_size": 10, "total_count": 2907, "total_pages": 291, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=80&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=78&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-03T16:29:48.581Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00694057", "title": "Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "HE3286", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Harbor Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 164, "start_date": "2008-06", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2011-06-14", "last_synced_at": "2026-11-03T16:29:48.581Z", "location_count": 22, "location_summary": "Anaheim, California • Beverly Hills, California • Buena Park, California + 17 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Buena Park", "state": "California" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00694057" }, { "nct_id": "NCT01478477", "title": "Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Recurrent Breast Cancer", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage II Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer" ], "interventions": [ { "name": "omega-3 fatty acid supplement", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Clinical assessments", "type": "OTHER" }, { "name": "Assessment of therapy complications", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Correlative/special studies", "type": "PROCEDURE" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER", "PROCEDURE" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 44, "start_date": "2011-10-04", "completion_date": "2014-01-09", "has_results": false, "last_update_posted_date": "2023-02-27", "last_synced_at": "2026-11-03T16:29:48.581Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01478477" }, { "nct_id": "NCT03374475", "title": "A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Depressive Disorder, Major" ], "interventions": [ { "name": "JNJ-42847922 20mg", "type": "DRUG" }, { "name": "JNJ-42847922 40mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 140, "start_date": "2018-01-05", "completion_date": "2019-04-29", "has_results": false, "last_update_posted_date": "2025-04-27", "last_synced_at": "2026-11-03T16:29:48.581Z", "location_count": 3, "location_summary": "San Diego, California • San Marcos, California • Miami, Florida", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Marcos", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03374475" }, { "nct_id": "NCT04678895", "title": "Low-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Painful Diabetic Neuropathy" ], "interventions": [ { "name": "Naltrexone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2020-12-22", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-11-03T16:29:48.581Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT04678895" }, { "nct_id": "NCT00666562", "title": "Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage I Bladder Cancer", "Stage II Bladder Cancer", "Stage III Bladder Cancer" ], "interventions": [ { "name": "Defined Green Tea Catechin Extract", "type": "DIETARY_SUPPLEMENT" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER", "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2008-07-02", "completion_date": "2017-06-09", "has_results": true, "last_update_posted_date": "2017-11-17", "last_synced_at": "2026-11-03T16:29:48.581Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Burlington, Massachusetts • Minneapolis, Minnesota + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Burlington", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Rochester", "state": "New York" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00666562" }, { "nct_id": "NCT05947383", "title": "Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer", "Major Depressive Disorder" ], "interventions": [ { "name": "Psilocybin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sunstone Medical", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2023-10-23", "completion_date": "2027-11-01", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-11-03T16:29:48.581Z", "location_count": 1, "location_summary": "Rockville, Maryland", "locations": [ { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05947383" }, { "nct_id": "NCT02717988", "title": "Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "SKI-O-703 capsule", "type": "DRUG" }, { "name": "Placebo capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oscotec Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 48, "start_date": "2015-09", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2018-02-28", "last_synced_at": "2026-11-03T16:29:48.581Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02717988" }, { "nct_id": "NCT03435003", "title": "Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Post-operative Nausea and Vomiting", "Laparoscopic Sleeve Gastrectomy" ], "interventions": [ { "name": "Aprepitant 80 mg Oral Capsule", "type": "DRUG" }, { "name": "scopolamine transdermal", "type": "DRUG" }, { "name": "Total intravenous anesthesia", "type": "PROCEDURE" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Ondansetron", "type": "DRUG" }, { "name": "Reglan", "type": "DRUG" }, { "name": "Compazine", "type": "DRUG" }, { "name": "Sugammadex", "type": "DRUG" }, { "name": "Propofol", "type": "DRUG" }, { "name": "dexmedetomidine", "type": "DRUG" }, { "name": "Fentanyl", "type": "DRUG" }, { "name": "Sevoflurane", "type": "DRUG" }, { "name": "Desflurane", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Stony Brook University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2017-08-28", "completion_date": "2019-04-01", "has_results": true, "last_update_posted_date": "2024-02-14", "last_synced_at": "2026-11-03T16:29:48.581Z", "location_count": 1, "location_summary": "Stony Brook, New York", "locations": [ { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03435003" }, { "nct_id": "NCT00655369", "title": "A Double-blind, Parallel Group, Placebo-Controlled Outpatient Trial of PD 00200390 in Adults With Nonrestorative Sleep", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nonrestorative Sleep" ], "interventions": [ { "name": "PD 0200390", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 306, "start_date": "2008-04", "completion_date": "2008-12", "has_results": false, "last_update_posted_date": "2012-07-25", "last_synced_at": "2026-11-03T16:29:48.581Z", "location_count": 52, "location_summary": "Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 45 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00655369" }, { "nct_id": "NCT04656860", "title": "Juice Plus Supplement Clinical Trial", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cognitive Impairment", "Alzheimer Disease, Early Onset", "Mild Cognitive Impairment" ], "interventions": [ { "name": "Juice Plus+", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "University of Alabama, Tuscaloosa", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "55 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "55 Years to 90 Years" }, "enrollment_count": 150, "start_date": "2020-03-12", "completion_date": "2023-03-12", "has_results": false, "last_update_posted_date": "2021-04-08", "last_synced_at": "2026-11-03T16:29:48.581Z", "location_count": 2, "location_summary": "Tuscaloosa, Alabama", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04656860" } ] }